Aug 2026· British Journal of Pharmacology· 0 citations· 191 references
Medicine
TL;DR
This work discusses new discoveries which highlight the value of lncRNA targeting as therapeutic applications, in gastrointestinal inflammation and cancer angiogenesis, and identifies gaps in the current knowledge and understanding.
Abstract
Long non-coding RNAs (lncRNAs), a broad class of non-protein-coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post-transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory, oncogenic and proangiogenic pathways. Inflammation, cancer and angiogenesis are interlinked through a network of signals and pathways that reinforces itself through feedback loops. Inflammation triggers vessel formation to transfer immune cells and nutrients, and consequently the new vessels enhance the supply of inflammatory cells and factors. Chronic inflammation induces oncogenic transformation and angiogenesis, induced by tumour-derived signals, support tumour growth and provide the route for distal metastasis. Here we review the implication of lncRNAs in these processes and interactions in the gastrointestinal tract, with a special focus on inflammation and cancer angiogenesis. LncRNAs, due to their highly cell-, tissue- and disease-specific expression, are attractive targets for the development of novel therapeutics with limited off-target effects and toxicity. We discuss new discoveries which highlight the value of lncRNA targeting as therapeutic applications, in gastrointestinal inflammation and cancer angiogenesis, and identify gaps in our current knowledge and understanding. We illustrate advancing approaches, their advantages and challenges for the pharmacological targeting of lncRNAs.
This review examines how different types of ncRNAs contribute to cancer initiation, progression, and treatment resistance, and assesses their potential as diagnostic markers, prognostic factors, and therapeutic targets.
Akanksha Samuel, G. Calin· Carcinogenesis· 0 citations
Colorectal cancer (CRC) and diabetes mellitus are major global health burdens that frequently coexist and share overlapping metabolic and molecular abnormalities. Accumulating epidemiological evidence indicates that diabetes is associated with an increased risk of CRC; however, the underlying mechanisms remain incompletely defined. Long non-coding RNAs (lncRNAs) have recently emerged as important regulators of gene expression and cellular signaling, with critical roles in both metabolic disorders and cancer. In this review, we summarize current evidence on key lncRNAs that are implicated in the shared molecular networks linking diabetes and CRC. These lncRNAs modulate multiple signaling pathways, including PI3K/AKT, Wnt/β-catenin, NF-κB–mediated inflammation, hypoxia-associated signaling, metabolic reprogramming, angiogenesis, and epigenetic regulation. Through interactions with microRNAs (miRNAs), transcription factors, and chromatin-modifying complexes, they influence key biological processes such as insulin signaling, glucose metabolism, epithelial–mesenchymal transition, oxidative stress responses, and tumor progression. Elucidating the roles of lncRNAs provides important insight into the molecular interplay between metabolic dysfunction and colorectal tumorigenesis. Notably, many lncRNAs are detectable in circulating fluids, highlighting their potential as non-invasive biomarkers for early detection and risk assessment in diabetic populations at increased risk of CRC. Furthermore, targeting dysregulated lncRNAs may offer novel therapeutic opportunities to simultaneously modulate metabolic and oncogenic pathways. Overall, integrating lncRNA biology into the study of CRC and diabetes may advance our understanding of disease mechanisms and support the development of improved diagnostic and therapeutic strategies.
Lu Zhang, Min Li· Frontiers in Molecular Biosc...· 0 citations
Metastasis and therapeutic resistance remain the principal causes of cancer-related mortality, reflecting the failure of current therapies to eradicate disseminated and treatment-refractory tumor cells. Long non-coding RNAs, once considered transcriptional noise, have now emerged as pivotal regulators of cancer progression, acting through diverse mechanisms to modulate signaling pathways, transcriptional programs, tumor metabolism, and the tumor microenvironment. Accumulating evidence demonstrates that lncRNAs orchestrate epithelial-mesenchymal transition, metabolic reprogramming, and immune evasion, thereby enabling metastatic dissemination and fostering resistance to chemotherapy. Moreover, recent discoveries have revealed that certain lncRNAs can encode functional micropeptides, further expanding their biological and therapeutic relevance. In this review, we systematically summarize current advances in lncRNA-mediated regulation of cancer metastasis and drug resistance, with particular emphasis on their roles in oncogenic signaling cascades, transcriptional control, immune cell reprogramming, and metabolic remodeling. we also discuss emerging therapeutic strategies targeting lncRNAs, including antisense oligonucleotides, CRISPR-based approaches, and lncRNA-encoded micropeptides interventions. Finally, we highlight key challenges, including context-dependent lncRNA functions, tumor heterogeneity, delivery, off-target effects, and biomarker standardization, and discuss multi-omics, single-cell, and spatial approaches may facilitate the translation of lncRNA biology into precision oncology.
Dong Liang, Jing-Wen Zheng, Zheng-Dan Gao et al.· Biochimica et biophysica act...· 0 citations
This review systematically explores the molecular mechanisms underlying the interactions between non-coding RNAs and alternative splicing events, highlighting the role of this regulatory network in modulating the expression of oncogenes and tumor suppressor genes in HCC.
This review will focus on the newly identified functions of non-coding RNAs (ncRNAs) in cancer biology and therapeutic innovations, and reviews the existing knowledge on microRNAs, long non-coding RNAs, and circular RNAs in the context of their different experimental and computational studies.
Li Qiu, Zenan Xu, Jianxiong Xu et al.· Biomolecules· 0 citations
These findings call for a revised molecular dogma in which the noncoding genome is recognized as a major regulator of cellular function, oncogenic transformation, and immune surveillance.
Maria Lteif, Assia Hijazi, E. Morgand et al.· Oncoimmunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
